BMEA - NASDAQ

Biomea Fusion, Inc.

BMEA·NASDAQ

$1.38

+6.2%

HealthcareBiotechnology

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$82.10M

EPS-1.1800

P/E Ratio-1.17

Earnings Date08/03/2026

58.57M

Assets

-27%

3Y-55.0%

5Y-6.0%

10Y+22003.0%

29.02M

Total Liabilities

3Y+40.0%

5Y-49.0%

10Y+10047.0%

29.55M

Total Equity

-43%

3Y-73.0%

5Y+472.0%

10Y-140824.0%

Biomea Fusion, Inc. Funding & Solvency Profile

BMEA · NASDAQ

Current Assets

Cash & Cash Equivalents55.81M

Net Receivables0.00

Inventory0.00

Other Current Assets2.24M

Total Current Assets58 M

Non-Current Assets

Property, Plant & Equipment153.00K

Goodwill & Intangible Assets0.00

Long-Term Investments369.00K

Other Non-Current Assets0.00

Total Non-Current Assets522 K

Total Assets

58.57M

Financial Health Analysis

Current Ratio

5.23x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.98x

Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.

Working Capital

47 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

99% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Biomea Fusion, Inc. Balance Sheet

BMEA • NASDAQ

Biomea Fusion, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	55.8M	58.3M	176.9M	111.9M	145.7M	61.7M	239K
Short-Term Investments	0.0	0.0	0.0	1.2M	27.8M	0.0	0.0
Cash & Short-Term Investments	55.8M	58.3M	176.9M	113M	173.5M	61.7M	239K
Prepaids	0.0	0.0	0.0	0.0	3M	528K	11K
Other Current Assets	2.2M	10.1M	2.3M	4.8M	0.0	0.0	0.0
Total Current Assets	58.1M	68.3M	179.2M	117.8M	176.6M	62.2M	265K
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	153K	10.6M	14.9M	8M	5.7M	291K	0.0
Long-Term Investments	369K	0.0	0.0	0.0	1.9M	0.0	0.0
Other Non-Current Assets	0.0	988K	5.9M	3.5M	1.6M	12K	0.0
Total Non-Current Assets	522K	11.6M	20.7M	11.5M	9.1M	303K	0.0
Total Assets	58.6M	79.9M	199.9M	129.3M	185.7M	62.5M	265K
LIABILITIES
CURRENT LIABILITIES
Total Payables	3.2M	12.9M	6.9M	6.8M	1.3M	727K	271K
Accounts Payable	3.2M	12.9M	6.9M	6.8M	1.3M	727K	271K
Accrued Expenses	0.0	6.5M	13.4M	11M	2.3M	633K	15K
Short Term Debt	0.0	0.0	0.0	0.0	0.0	36K	0.0
Capital Lease Obligations (Current)	1.5M	2.1M	2.5M	618K	565K	223K	0.0
Other Current Liabilities	6.4M	203K	192K	636K	480K	0.0	0.0
Total Current Liabilities	11.1M	21.7M	22.9M	19.1M	4.6M	1.6M	286K
NON-CURRENT LIABILITIES
Other Non-Current Liabilities	17.8M	0.0	0.0	0.0	0.0	55.7M	0.0
Total Non-Current Liabilities	17.9M	6.7M	7.8M	1.7M	2.3M	55.7M	0.0
Capital Lease Obligations	1.6M	8.8M	10.3M	2.3M	2.9M	223K	0.0
Total Liabilities	29M	28.4M	30.7M	20.8M	6.9M	57.4M	286K
SHAREHOLDERS' EQUITY
Common Stock	7K	4K	4K	3K	3K	1K	1K
Additional Paid-In Capital	478.6M	438.8M	418.1M	240.1M	228.5M	13.3M	2.8M
Retained Earnings	-449M	-387.3M	-248.8M	-131.6M	-49.7M	-8.2M	-2.9M
Accumulated Other Comprehensive Income/Loss	0.0	0.0	0.0	-1K	-10K	0.0	0.0
Total Stockholders' Equity	29.6M	51.6M	169.2M	108.5M	178.8M	5.2M	-21K
Total Equity	29.6M	51.6M	169.2M	108.5M	178.8M	5.2M	-21K
SUMMARY
Total Liabilities & Equity	58.6M	79.9M	199.9M	129.3M	185.7M	62.5M	265K
Total Investments	369K	0.0	0.0	1.2M	29.7M	0.0	0.0
Total Debt	1.6M	8.8M	10.3M	2.3M	2.9M	259K	0.0
Net Debt	-54.2M	-49.5M	-166.6M	-109.6M	-142.9M	-61.4M	-239K
Shares Outstanding	59,496,296	59,496,296	59,496,296	59,496,296	59,496,296	59,496,296	59,496,296

SEC Filings

BMEA - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 11, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 11, 2026	May 11, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 28, 2026	April 27, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 27, 2026	June 10, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 24, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 24, 2026	March 24, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 25, 2026	February 25, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 14, 2026	January 14, 2026	2026	View Filing
10-Q 10-Q 2025 Q3 Q3	November 04, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 04, 2025	November 04, 2025	2025	View Filing

Showing 1 to 10 of 101 filings

Related Guides

Blog Categories

Continue your BMEA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.